OXALIPLATINE INJ 50 MG

This tender, originating from Jordan and accessible through joneps_jo, is for the supply of Oxaliplatin Injection, 50 mg. The contracting authority is seeking to procure a specific injectable chemotherapeutic agent. This procurement is critical for oncology departments within healthcare facilities. As with other pharmaceutical tenders, typical requirements mandate that the Oxaliplatin Injection must be a registered product with the Jordanian Food and Drug Administration (JFDA) or equivalent authority. Bidders will need to provide comprehensive documentation, including proof of GMP compliance for manufacturing, Certificates of Analysis (CoA) for each batch, and detailed product information such as formulation, concentration, vial size, and storage conditions. The tender will likely emphasize the importance of product quality, sterility, and stability. Suppliers are expected to demonstrate a robust supply chain capable of delivering temperature-sensitive or specialized medications, adhering to strict handling and storage protocols. Experience in supplying oncology drugs and a proven track record of reliability will be highly valued by the procuring entity.